Absci Corporation (ABSI) has priced an underwritten public offering of 16.67 million shares of its common stock at $3.00 per share, expected to generate $50 million in gross proceeds. The offering, closing around July 25, 2025, will support Absci’s internal pipeline and development of its Integrated Drug Creation platform. All shares will be sold by Absci, with an option for underwriters to purchase an additional 2.5 million shares. ABSI currently trades at $2.855 on the NasdaqGS, 18.6610% lower.

Read more at Nasdaq: Absci Prices $50 Mln Public Offering To Advance AI-Driven Drug Programs